SEC Alleges Pharma Co. Misled Investors About Cancer Drug

By Jessica Corso · February 6, 2026, 7:11 PM EST

The U.S. Securities and Exchange Commission is suing a Kentucky pharmaceutical company for securities fraud based on claims that the company raised $4.1 million by lying to investors about the status...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Complaint

Case Information

Case Title

United States Securities and Exchange Commission v. CBA Pharma Inc. et al

Case Number

Court

Kentucky Eastern

Nature of Suit

Securities/Commodities

Date Filed

February 05, 2026

Recent Articles By Jessica

December 23, 2025
AdaptHealth To Pay Investors $35M To End Inflated-Sales Suit
September 22, 2025
J&J Ruling Misapplied Goldman Precedent, 3rd Circ. Told
March 24, 2025
Kenvue, J&J Must Face Investor Suit Over FDA Concerns
December 03, 2024
SEC Says Biopharma's Cooperation Helped It Avoid Penalty
August 13, 2024
Judge Urged To Toss Novel Insider Trading Conviction
May 16, 2024
3rd Circ. Shuns Teva's 'Novel' Appeal On Israeli Investor Class
March 25, 2024
COVID 'Cure' Claims Can't Sustain Fraud Suit, 9th Circ. Rules
March 08, 2024
Judge Keeps Novel Insider Trading Indictment Alive
October 04, 2023
Justices Urged To Halt All In-House Cases Until Congress Acts
September 26, 2023
Accounting Board Fines BDO $2M Over Missed Red Flags